Progestogen only contraception in women with congenital heart disease

References

• Abarbanell, G., et al., 2019. Safety of contraceptive use among women with congenital heart disease: a systematic review. Congenital Heart Disease, 14 (3), 1–8.
   Web of Science ®Google Scholar
• Anon, et al., 2015. WHO guidelines approved by the guidelines review committee. Medical eligibility criteria for contraceptive use. Geneva: World Health Organization.
   Google Scholar
• Bédard, E., Dimopoulos, K., and Gatzoulis, M.A., 2009. Has there been any progress made on pregnancy outcomes among women with pulmonary arterial hypertension? European Heart Journal, 30 (3), 256–265.
   PubMed Web of Science ®Google Scholar
• Cannobio, M., et al., 2017. Management of pregnancy in patients with complex congenital heart disease: a scientific statement for healthcare professionals from the American Heart Association. Circulation, 135, e50–e87.
   PubMed Web of Science ®Google Scholar
• Cox, M., et al., 2002. Clinical performance of the levonorgestrel intrauterine system in routine use by the UK Family Planning and Reproductive Health Research Network: 5-year report. Journal of Family Planning and Reproductive Health Care, 28 (2), 73–77.
   PubMed Web of Science ®Google Scholar
• Fry, K.M., et al., 2015. Lifetime prevalence of sexual intercourse and contraception use at last sex among adolescents and young adults with congenital heart disease. Journal of Adolescent Health, 56 (4), 396–401.
   PubMed Web of Science ®Google Scholar
• Giang, K.W., et al., 2021. Burden of ischemic stroke in patients with congenital heart disease: a nationwide, case-control study. Journal of the American Heart Association, 10 (13), e020939.
   PubMed Web of Science ®Google Scholar
• Habib, G., et al., 2015. ESC guidelines for the management of infective endocarditis: the Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). European Heart Journal, 36 (44), 3075–3128.
   PubMed Web of Science ®Google Scholar
• Lindley, K., et al., 2021. Contraception and reproductive planning for women with cardiovascular. Journal of the American College of Cardiology, 77 (14), 1823–1834.
   PubMed Web of Science ®Google Scholar
• Mansour, D., et al., 2010. Efficacy of contraceptive methods: a review of the literature. European Journal of Contraception & Reproductive Health Care, 15 (1), 4–16.
   PubMed Web of Science ®Google Scholar
• Marelli, A.J., et al., 2014. Lifetime prevalence of congenital heart disease in the general population from 2000 to 2010. Circulation, 130 (9), 749–756.
   PubMed Web of Science ®Google Scholar
• Meyerowitz, E.A., et al., 2019. Endocarditis following IUD insertion in a patient with tetralogy of Fallot. BMJ Case Reports, 12 (2), e227962.
   PubMedGoogle Scholar
• Miner, P., et al., 2017. Contraceptive practices of women with complex congenital heart disease. American Journal of Cardiology, 119 (6), 911–915.
   PubMed Web of Science ®Google Scholar
• Moray, K.V., et al., 2021. A systematic review on clinical effectiveness, side-effect profile and meta-analysis on continuation rate of etonogestrel contraceptive implant. Reproductive Health, 18 (1), 4.
   PubMed Web of Science ®Google Scholar
• Palacios, S., et al., 2020. Bleeding profile of women using a drospirenone-only pill 4 mg over nine cycles in comparison with desogestrel 0.075 mg. PLOS One, 15 (6), e02318.
   Web of Science ®Google Scholar
• Pijuan-Domènech, A., et al., 2013. Usefulness of progesterone-only components for contraception in patients with congenital heart disease. American Journal of Cardiology, 112 (4), 590–593.
   PubMed Web of Science ®Google Scholar
• Regitz-Zagrosek, V., 2018. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. European Heart Journal, 39 (35), 3241–3269.
   Web of Science ®Google Scholar
• Roos-Hesselink, J.W., et al., 2015. Contraception and cardiovascular disease. European Heart Journal, 36 (27), 1728–1734.
   PubMed Web of Science ®Google Scholar
• Runyan, L., et al., 2021. Acting reversible contraception: placement continuation, and removal rates at an inner-city academic medical center clinic. Journal of Clinical Medicine, 10 (9), 1918.
   PubMed Web of Science ®Google Scholar
• Thorne, S., et al., 2006. Risks of contraception and pregnancy in heart disease. Heart (British Cardiac Society), 92 (10), 1520–1525.
   PubMed Web of Science ®Google Scholar
• Trinh, A., et al., 2023. Contraception and cardiovascular effects: what should the cardiologist know? Current Cardiology Reports, 25 (11), 1489–1498.
   PubMed Web of Science ®Google Scholar
• Warnes, C.A., et al., 2008. ACC/AHA 2008 guidelines for the management of adults with congenital heart disease: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (writing committee to develop guidelines on the management of adults with congenital heart disease). Circulation, 118, e714–e833.
   PubMed Web of Science ®Google Scholar